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Malignant Hyperthermia (MH) • Since MH is a fast MH is an autosomal dominate Published data of MH incidence Once Malignant Hyperthermia is • Complications associated • According to the genetic disorder of the suspected	 many nursing interventions	 progressing, lethal disease 
International is more than likely need to happen	 quickly in	 order to with MH come from the process, “The Malignant 
Classification of Diseases, skeletal muscle resulting in a underreported than what	 is reverse the deadly cascade that can exposure	 of the	 triggering Hyperthermia Association hyperthermic reaction to a seen in literature. ensue	 with MH. agent that leads to MH is a rare, but trigger such as violate • Registered Nurses as well as of the United States progressive, and life- • MH is typically more Certified Registered Nurse uncontrolled release of (MHAUS)	 guidelines state 
threatening	 hyperthermic anesthetic	 gases or the	 common in males, with Anesthetists (CRNA) should be calcium	 from	 the	 skeletal that	 dantrolene must	 be depolarizing neuromuscular males making up about 68% educated on MH signs and muscles (Haili &	 Weant,	 reaction following the symptoms. available	 within 10min of blocking agent, administration of general of cases. • Nurses working in the Post 2021). the decision to treat	 MH at	 
anesthesia	 (Hopkins et. al., Succinylcholine. • Any age, race, gender, or Anesthesia Care Unit (PACU), the • The continuously muscle all anesthetizing/ sedating • In	 a patient who ethnicity can be at risk. operating room (OR), and the contraction causes 2020) experiences MH, there is intensive care units (ICU)	 should be locations where MH-• With early detection and • The mean age for reported specially trained	 because these “increased CO2 production triggering	 agents are used.	 genetic issues with the MH cases is 21 to 23 years environments are	 where	 MH is as a	 by-product of ATP intervention MH can be until	 adequate	 response	 is calcium	 channels in most likely to occur due to the old. generation in the treated. Without	 medications and anesthetic gas achieved.	 MHAUS 
immediate treatment skeletal muscle. • MH tends to occur after administered. mitochondria, excess heat mandates that each • Predominately mutations more	 then one	 exposure	 of • If	a 	nurse 	suspects 	MH, 		100% production from the rapid mortality	 rate	 is in the ryanodine receptor anesthesia but can occur on oxygen should be started via a consumption of ATP, and 
institution stock at 
significantly higher (Yang nonrebreather mask if not least 720mg of 
et. al., 2020). 
type 1 (RYR1) gene. the first exposure	 to a mechanically ventilated in the OR. increased lactate dantrolene—sufficient to • There are currently 29 triggering	 agent. • The provider and anesthesia should production as the body Why MH?	 known mutations	 in the • Patients under the age 15 be notified immediately, and attempts to produce	 administer 10mg/kg to a	 • MH can happen at any age, RYR1 gene. someone should	 retrieve the MH 70-kg patient”	 (Larach et. make	 up about 52% of the	 chart. energy	 by	 anaerobic	 but it tends to	 happen • This mutation causes the cases of MH. • The primary nurse should stay at metabolism “	 (Haili &	 al.,	 2019) • Any health care provider more	 often in young adults actin–myosis–troponin • Recent studies show that bedside with the patient and Weant,	 2021). and children (Gupta	 & monitor vitals signs	 via cardiac in an environment where 
Hopkins, 2017). 
interaction to occur the genetic mutation in the monitors. • These each lead to cell MH is possible, must be leading to muscle RYR1 gene is about 1 in • The IV lines should be checked to destruction releasing high educated and aware	 of MH • MH is a disease process contraction, ultimately verify patency so that the 2,000	 to 1	 in 3,000	 levels of potassium and that	 although rare can being the cause of the frequency. medications can be administered 
signs	 and	 symptoms	 and	 
creatine	 kinase	 into the	 once available. treatment	 in order to act	 become fatal quickly. hypermetabolic response. (Malignant hyperthermia • Take measures to reduce body blood stream which quickly to	 save the • The mortality	 from MH is • In	 MH, the relaxation of temperature such as removing (NORD), 2013) potentially can cause approximately 6 to 12% in muscle	 is inhibited, but https://i.pinimg.com/originals/c1/1e/01/c11e017497aeded54bc8c96eb412cc03.jpg extra	 sheets, cool IV fluids, ice	 patient. 
packs, or a cooling blanket. cardiac	 arrythmias or the United States (Gupta & calcium	 is continuously • Place a foley catheter to monitor renal failure (Haili &	 Hopkins, 2017) released causing nonstop Treatments kidney function. Weant,	 2021). References • Draw frequent 	labs 	to 	monitor Signs &	 Symptoms muscle	 contraction. Early identification and Intervention is key to patient survival electrolytes, pH, and renal function. • Calcium Channel blockers 
• The most common (Haili &	 Weant,	 2021) • Once MH is suspected the anesthesia provider must stop the • Once the patient has been stabilized should	 be avoided	 when 
diagnostic characteristics	 Image 1. Pathophysiology	 of Malignant Hyperthermia administration of the	 inhaled anesthetic	 and begin to and transferred to the	 ICU, administering Dantrolene	 Dantrolene will continue to be 
of MH	 include unexplained hyperoxygenate the patient	 at	 100% FiO2. administered every 4 to 6 hours for because together they can 
rise in ETCO2, increase in • Begin the administration of the medication Dantrolene the next	 24 to 48 hours to prevent	 cause	 hyperkalemia	 which 
heart rate, and a rapid following the guidelines. recurrent MH episode. can lead to cardiac	 • Before discharge from the hospital • Actively being cooling measure to get patient’s core body increase in temperature. the nurse should educate the dysrhythmias	 or cardiac 
• Others include masster temperature lowered. patient on their new medical arrest. (Wolters Kluwer, 
spasm, muscle rigidity, • If not already present, establish invasive	 monitoring devices to history and explain the importance 2006)
of making medical providers and monitor for hemodynamic	 stability. dark	 colored	 urine, and	 family 	aware 	to 	prevent 	future • Another potential 
sweating. • Collect routine lab work, watching closely for hyperkalemia, episodes. complication can be 
• Family history of	 MH is an acidosis, and indicators of renal injury. • Provide the patient with written disseminated	 information about MH and 
important indicator. • Once the patient is medically stable, transfer to the critical care resources to learn more. intravascular coagulation 
(Yang et. al., 2020) unit for further treatment and observation (DIC)	 (Wolters Kluwer, 
Laitano et. Al., 2020 (Gupta and Hopkins, 2017) (Wolter Kluwer, 2006) 2006) 
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